President Biden Relaunches Cancer Moonshot Program

On February 7, 2022, President Biden relaunched his Cancer Moonshot initiative in order to "end cancer as we know it." Cancer Moonshot, which President Biden originally launched as Vice President in 2016 after his son Beau Biden died in 2015 of glioblastoma, has ambitious goals including:

- Over the next 25 years, Cancer Moonshot will cut today’s age-adjusted death rate from cancer by at least 50%.
- Improve the experience of people and their families living with and surviving cancer.

Cancer Moonshot is President Biden’s first attempt as President to tackle curing cancer, which was one of his signature issues on the campaign trail. In order to help accomplish his Cancer Moonshot goals, President Biden also pressed Congress to fund the Advanced Research Project Agency for Health (ARPA-H), which he hopes will be housed within the National Institutes of Health. ARPA-H funding has already been included in appropriations legislation in Congress. However, the program will not be established until Congress passes the FY2022 appropriations package. View the White House Press Release on Cancer Moonshot here.

Upcoming and On-Demand Webinars

The Pediatric Special Interest Track is pleased to present the next broadcast of the Pediatric Tumor Board Series. The broadcast entitled Embryonal tumor with multilayered rosettes (ETMR): Evidence-based recommendations for the diagnosis and treatment of this biologically and clinically heterogeneous pediatric CNS tumor will occur live on March 22, 2022, 10:00-11:30 am ET. Click here to register.

If you did not have the opportunity to catch the webinar, "The Neural Regulation of Cancer," jointly sponsored by the World Federation of Neurology and the Society of Neuro-Oncology, it is available on-demand here.

Educational Programming

Clinical trial accrual for women and minorities in neuro-oncology.
Dr. Rachna Malani interviews Dr. Hervey-Jumper about his and his team's recent manuscript entitled "A population study of clinical trial accrual for
From The Journals

The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications. Infiltrative astrocytic tumors with and without isocitrate dehydrogenase (IDH) mutation frequently contain mutations in the TP53 tumor suppressor gene. Disruption of normal p53 protein activity confers neoplastic cells with a number of oncogenic properties and is a common feature of aggressive malignancies. However, the high prevalence of TP53 mutation and its pathogenic role in IDH-mutant (IDHmut) astrocytoma is not well understood. Click to read the full article.

SNO Career Center

This Week's Featured Listing
The Allegheny Health Network (AHN) is recruiting full-time Neuro Oncology physicians to join their expanding team in Pittsburgh, PA! Click here to apply or see other postings!

Upcoming SNO and SNO Affiliated Events

2022 SNO Annual Meeting and Education Day - Call for Abstracts
Abstract deadline - June 1, 2022
For information on the submission categories and requirements, please click here.
To submit an abstract, please click here.

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)
June 12-15, 2022, in Hamburg
Register Here
For information about travel grants for LMIC countries, please click here.

2022 SNO Introduction to Clinical Trial Design and Protocol Development Workshop
August 11, 2022
Application deadline - April 15, 2022
Apply Here

2nd Annual Conference on Clinical Trials and Brain Metastases
August 12-13, 2022
Call for Abstracts - Deadline: April 18, 2022
Submit Your Abstract
SNO Membership

The Society for Neuro-Oncology represents over 2,800 professionals dedicated to promoting advances in neuro-oncology through research and education. As part of this commitment, SNO is pleased to introduce a **new category of membership for Allied Health Professionals**. This category of memberships is designed for non-physician clinical health care professionals, including, advance practice professionals, nurses, physician assistants, pharmacists, and others who spend most of their professional activity on the treatment and care of patients with brain and CNS tumors. [Click here for more information.](#) **Now is the time to renew your membership or join the Society.** Click [here](#) today to get started.

*SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.*

---

**Society for Neuro-Oncology | Website**

[Subscribe to the SNO Digest](#)

---

See you in Tampa Bay!

27th Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022

---

Society for Neuro-Oncology | PO 273296, Houston, TX 77277

Unsubscribe [megan@soc-neuro-onc.org](mailto:megan@soc-neuro-onc.org)

[Update Profile](#) | [About Constant Contact](#)

Sent [bysnodigest@soc-neuro-onc.org](mailto:bysnodigest@soc-neuro-onc.org) in collaboration with

---

Try email marketing for free today!